Optimi Health Advances Psychedelic Therapy Trials

Optimi Health (TSE:OPTI) has released an update.

Optimi Health Corp. has partnered with ATMA Journey Centers to supply GMP psilocybin for Phase II clinical trials aimed at treating Major Depressive Disorder. The agreement, which covers territories including North America and the EU, positions Optimi as the sole supplier, with plans for a future collaboration on Phase III trials in 2025. This strategic alliance is anticipated to enhance accessibility and cost-effectiveness of psychedelic-assisted therapies, while ensuring high-quality standards and regulatory compliance.

For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.